Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

To compare the penetration of three different NSAIDs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vitrectomy

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ophthalmic Consultants of Boston

Boston, Massachusetts, 02114, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Males or females scheduled to undergo Vitrectomy surgery
Likely to complete all study visits and able to provide informed consent
Visual potential of 20/25 or better

Exclusion criteria

Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease
Active ocular allergies

Treatment and study plan

Nepafenac

Drug

Ketorolac LS, Bromfenac

Drug

Sponsors and collaborators

Lead sponsor

Innovative Medical

Industry

Registry information

Important dates

First posted: Sep 18, 2006
Registry last updated: Sep 25, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed